RFK Jr. Is Supporting mRNA Analysis—Simply Not for Vaccines
[ad_1] One of many focused recipients, Tiba Biotech, had a $750,000 contract with BARDA that was slated to finish October 30. The corporate was creating an RNAi-based therapeutic for H1N1 influenza, also called swine flu. RNAi is brief for RNA interference
